Novartis | NVS - Sales Revenues


Novartis reported $14.36B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bausch Health Companies USD 2.8B 120M Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
J&J USD 24.6B 610M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pacira USD 179.52M 1.58M Sep/2025
Perrigo USD 1.04B 16.3M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Phibro Animal Health USD 309.26M 48.83M Dec/2024
Prestige Brands USD 283.44M 9.34M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sanofi EUR 12.2B 3.19B Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Zoetis USD 2.4B 0 Dec/2025